Investing.com - Financial Markets Worldwide

Chengdu Easton Biopharmaceuticals Co Ltd (688513)

Shanghai
Currency in CNY
60.50
-3.80(-5.91%)
Closed·

688513 Financial Summary

Key Ratios

P/E Ratio49.2
Price/Book3.94
Debt / Equity5.18%
Return on Equity8.31%
Dividend Yield0.71%
EBITDA249.79M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
01/01
2015
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa921.921,022.941,170.511,117.121,349.76
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa814.23876.62971.4890.181,004.53
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa118.72135.47157.4152.2168.42
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa178.16232.43246.52226.57238.23
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa2,530.862,775.273,017.543,346.753,400.13
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa385.28432.46529.39661.09596.32
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa2,095.252,291.662,444.462,603.422,697.92
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa-59.72-90.64-258.547.75-13.92
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa156.52147.6151.94275.25263.24
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-756.63-110.59-405.7-410.17196.63
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa1,251.36-56.439.780.67-262.27
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa651.23-19.39-214.04-54.32197.64
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.27%
Dividend Yield
0.71%
Industry Median 1.51%
Annualised payout
0.43
Paid annually
5-Years Growth
-
Growth Streak
Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 43.00
(-28.93% Downside)

Earnings

Latest Release
Apr 24, 2025
EPS / Forecast
0.34 / --
Revenue / Forecast
305.64M / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Chengdu Easton Biopharmaceuticals's earnings for the latest quarter?

The Chengdu Easton Biopharmaceuticals EPS (TTM) is 1.27. Chengdu Easton Biopharmaceuticals reported sales of 305.64, net income of 60.59, and EPS of 0.34 for the latest quarter.

What was Chengdu Easton Biopharmaceuticals's net income for the latest quarter?

Chengdu Easton Biopharmaceuticals's net income for the latest quarter was 60.59.

How did Chengdu Easton Biopharmaceuticals's performance compare year-over-year in the latest quarter?

The company's revenue moved from 309.82 in the previous quarter to 305.64 in the latest quarter, and net income moved from 21.21 to 60.59 compared to the previous quarter.

What is Chengdu Easton Biopharmaceuticals's net profit margin on a TTM basis?

Chengdu Easton Biopharmaceuticals's trailing twelve months (TTM) net profit margin is 17.65%.

How does Chengdu Easton Biopharmaceuticals's debt to equity ratio compare to industry standards?

Chengdu Easton Biopharmaceuticals's total debt-to-equity ratio is 5.18%.

What is Chengdu Easton Biopharmaceuticals's return on investment on a TTM basis?

Chengdu Easton Biopharmaceuticals's trailing twelve months (TTM) return on investment (ROI) is 8.31%.

Did Chengdu Easton Biopharmaceuticals gain or lose cash last quarter?

In the latest quarter, Chengdu Easton Biopharmaceuticals's net change in cash was -474.18 million.

What were Chengdu Easton Biopharmaceuticals's total assets and liabilities in the latest quarter?

As of the latest quarter, Chengdu Easton Biopharmaceuticals reported total assets of 3,460.85 million and total liabilities of 593.43 million.

How has Chengdu Easton Biopharmaceuticals's total revenue grown this year?

Chengdu Easton Biopharmaceuticals's total revenue was 309.82 in the previous quarter and 305.64 in the latest quarter.

What is Chengdu Easton Biopharmaceuticals's gross margin on a TTM basis?

Chengdu Easton Biopharmaceuticals's trailing twelve months (TTM) gross margin is 74.23%.

What was Chengdu Easton Biopharmaceuticals's revenue per share for the latest quarter?

Chengdu Easton Biopharmaceuticals's revenue per share for the latest quarter was 6.99.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.